Despite the clear association between atrial fibrillation and risk for thromboembolic events (TEs), the clinical significance of new-onset device-detected atrial tachyarrhythmia (DDAT) and TE remains disputed. We aimed to determine the risk of TE in patients with newonset DDAT.
Circ Arrhythm Electrophysiol. 2018;11:e005393. DOI: 10.1161/CIRCEP.117. 005393 March 2018 2 A trial fibrillation (AF) is recognized as the most commonly occurring, clinically significant arrhythmia in humans. The Framingham data indicate that ≈1 in 4 people who live past the age of 40 years will develop AF, 1 and AF is associated with a dramatically increased risk of thromboembolic events (TE). 2, 3 Typically, this has been attributed to Virchow's triad that creates an environment in which thombi, both intracardiac and extracardiac, may form and potentially embolize. 4, 5 Accordingly, work-up for stroke includes an ECG, and if no specific abnormalities are found, prolonged portable cardiac rhythm monitoring to evaluate for AF, or other clinically significant atrial tachyarrhythmia (AT). However, even while using ECGs, inpatient telemetry, Holter monitors, and looping event monitors ranging from 24 hours to 30 days-AT often goes undetected because it is frequently paroxysmal and asymptomatic. 6, 7 With increased use of cardiac devices capable of continuous, prolonged monitoring, recognition of even minimal burdens of AT has become increasingly common. Nevertheless, with wide ranges in the diagnostic thresholds for AT, studies have reported variable incidences of device-detected atrial tachyarrhythmia (DDAT). 8, 9 Furthermore, although the association between AF and risk for TE is established, the clinical significance of DDAT-and more saliently, the correlation between duration of AT and risk of TE-has not been fully elucidated. Studies have indicated AT burdens ranging from 5 minutes 10,11 to 5.5 hours 12 to be associated with an
WHAT IS KNOWN?
• The clinical diagnosis of atrial fibrillation has a well-established association with a significantly increased risk of thromboembolic events (TE).
• Increased use of implantable cardiac devices has led to increased diagnosis of device-detected atrial tachyarrhythmia (DDAT), but the association between DDAT and subsequent TE remains unclear.
WHAT THE STUDY ADDS?
• DDAT is diagnosed in almost one quarter of patients with implantable cardiac devices, and it is associated with a significant risk of subsequent TE, comparable to that of clinically diagnosed atrial fibrillation.
• Adjudication of DDAT is associated with increased rate of diagnosis of true atrial fibrillation, and higher risk of TE, when compared with nonadjudicated TE.
• Prolonged duration of DDAT (≥5 minutes) is associated with higher risk of TE compared with use of lower diagnostic threshold (<1 minute). increased risk of TE. No studies, however, have been able to consistently correlate a temporal relationship between episodes of AT and TE. [13] [14] [15] [16] [17] In addition, even though DDAT may be associated with increased risk of TE, it still remains unclear what minimal AT episode duration is clinically relevant. Although there is an established benefit of anticoagulation in patients with nonvalvular AF, 18, 19 there has been no consensus on proper use of these agents in the DDAT population with low overall burdens of AT.
Our study sought to analyze the literature for incidence of DDAT and the associated risk of TE, as well as evaluate the correlation between diagnostic threshold for DDAT used and risk of subsequent TE.
METHODS
The data, analytic methods, and study materials are described below. Because this study was a meta-analysis of published results, it did not require specific institutional review board approval. All information can be found within the included studies, except when additional details were provided by authors. The original corresponding authors should be contacted for additional data for future analyses or for the purposes of reproducing or replicating the results, as needed.
Search Strategy
A comprehensive literature search of the OVID Medline, Cochrane, and Scopus databases (inception through November 7, 2016) was conducted. A similar search strategy was used for each database-search terms can be seen in Table I in the Data Supplement. Articles were restricted to English language manuscripts. Case reports, conference abstracts, letters to the editor, reviews, and book chapters were not included in this meta-analysis. The Preferred Reported Items for Systematic Reviews and Meta-Analyses guidelines were applied during the search process.
Criteria for Study Selection
Randomized controlled trials, prospective, and retrospective studies reporting incidence of DDAT were selected for meta-analysis. Study inclusion criteria included prospective or retrospective analyses of patients with no prior history of AF or AT (although if present, results had to be amenable to removal of patients with AF/AT history) and prolonged (ie ≥3 months) cardiac monitoring with either pacemaker, implantable cardioverter defibrillator, or cardiac resynchronization therapy device. Implantable loop recorders were excluded because there is no dedicated atrial sensing in these devices. Exclusion criteria for studies included those with mixed results between patients with and without history of AF/AT that were unable to be separated or with a short monitoring period (ie, <3 months). Two reviewers (M.B. and C.S.) assessed the quality of the studies for eligibility in the meta-analysis. When necessary, authors of the original studies were contacted for further details or data. In cases where there was a disagreement during the eligibility assessment process, a third reviewer (G.U.) assessed the discrepancy, and decisions were reached by consensus. Quality of the data was analyzed using the Downs and Black Checklist or the Cochrane Risk of Bias tools, as applicable, by study type.
Data Extraction
Data were independently extracted from the included studies by 2 reviewers (M.B. and C.S.) and compared. Any discrepancies resulted in re-evaluation of the primary data and involvement of a third reviewer (G.U.), with disagreements resolved by consensus. Extracted data included baseline characteristics before study enrollment, specifically age, sex, CHADS 2 or CHA 2 DS 2 -VASc score, diagnoses of heart failure (HF), hypertension, diabetes mellitus, and prior history of coronary artery disease, myocardial infarction, or TE. Of note, most studies reported mean for age and follow-up time period. However, some studies only reported median, which was used as a measure of center when mean was not available.
The primary outcome was DDAT incidence, and the secondary safety outcome was TE events occurring after study enrollment. Special attention was placed in identifying diagnostic thresholds for duration of AT in each study, as well was the use of adjudication of device atrial electrograms (AEGs). In the event of any discrepancies in the data, the study authors were contacted for further information. Last, the use of antiplatelet or anticoagulant agents before, and at the end, of the study were also extracted when available.
Statistical Analysis
Statistical analysis was performed using Review Manager version 5.3 by Cochrane. A Mantel-Haenszel random effects model was used to calculate the relative risk (RR) with its corresponding 95% CI. The weighting of studies was calculated by sample size. The Bonferroni correction was applied in evaluation for multiple tests. Five tests were conducted, which required a P<0.01 to achieve significance. To assess the heterogeneity among the studies included, the I 2 statistic were calculated. For the I 2 statistic, the value was interpreted according to the following: 0% to 40% low overall heterogeneity; 30% to 60% moderate heterogeneity; 50% to 90% substantial heterogeneity; and 75% to 100% representing high heterogeneity. A funnel plot along with the Egger test was used to evaluate for publication bias using STATA version 15 (see Figure I in the Data Supplement).
RESULTS

Baseline Characteristics
Of 4893 reports identified, 95 were selected for abstract review, 51 completed full-text review, and 28 were selected for inclusion in this meta-analysis ( Figure 1 ). All 28 studies specifically evaluated for DDAT while 13 (46%) of the studies used DDAT as the primary outcome of interest. Another 8 studies (29%) used composite clinical outcomes (eg, all-cause mortality, cardiovascular mortality, HF hospitalization, etc) as the primary out-Circ Arrhythm Electrophysiol. 2018;11:e005393. DOI: 10.1161/CIRCEP.117.005393
March 2018 4 come measure, and 5 (18%) were interested primarily in incidence of stroke. Eleven included studies reported data from dual-chamber pacemaker only patients while 8 studies used solely cardiac resynchronization therapy devices. The remaining 9 studies used a combination of dual-chamber pacemaker, cardiac resynchronization therapy, and implantable cardioverter defibrillator devices. A total of 24 984 patients were followed in the included studies. Average age was 69.9 years, 34.7% were women, and 45.5% had diagnosis of HF (Table 1;  Table II in the Data Supplement). [10] [11] [12] [15] [16] [17] Ten studies provided baseline demographics information for patients with and without subsequent DDAT after enrollment. 10, 11, 15, 17, 21, 28, 32, 35, 39, 40 Patients with HF later went on to demonstrate higher incidence of DDAT (RR, 1.45; 95% CI, 1.01-2.09; P=0.04) although there were no significant differences in reported baseline characteristics (hypertension, diabetes mellitus, age, TE history, coronary artery disease history, or history of HF; see Table 2 and Figure II in the Data Supplement). CHADS 2 score was recorded when available but was only noted at baseline and, therefore, may have changed subsequently for enrolled patients. There was no notable difference between CHADS 2 scores between subjects who did or did not develop DDAT ( Figure III in the Data Supplement).
AT Incidence and DDAT Diagnostic Threshold
At the time of study initiation, 22 330 (89.4%) had no prior history of AT or AF. Subsequently, new-onset DDAT was recorded in 5128 of the 22 330 patients (23.0%) over a mean study duration of 21.8±18.6 months. However, there was a marked difference meta-analyzing those studies with adjudicated AEGs alone, which reported a 17.8% incidence rate of DDAT compared with 28.7% rate in studies that did not adjudicate AEGs.
The diagnostic threshold for new-onset DDAT in these studies ranged from arrhythmias <30 seconds to >150 minutes, with 22 studies (78.6%) using a cutoff of ≤5 minutes. Increased length of AT diagnostic threshold was associated with decreased rates of incidence. There was a 26.2%, 19.7%, and 16.4% incidence rate of AT noted in studies with ≤1 minute (13 studies), >1 to 5 minute (9 studies), and >5 minute (6 studies) diagnostic threshold, respectively (Figure IV in the Data Supplement).
TE Incidence and Association With DDAT
In total, 9 of the 28 studies (evaluating 8181 patients) reported TE. The overall incidence of TE was 2.1% over a mean follow-up time of 22.8±24 months. Of the 2023 patients with new-onset DDAT, 75 demonstrated TE (3.7%), more than twice the TE prevalence among patients who remained in normal sinus rhythm (97 of 6158 patients or 1.6%). This correlated with a significantly greater risk of TE among patients with new-onset DDAT compared with those who remained in normal sinus rhythm (RR, 2.88; 95% CI, 1.79-4.64; P<0.001) and was associated with a low degree of statistical heterogeneity (I 2 =33%; Figure 2 ). There was no significant publication bias noted across these studies ( Figure I in the Data Supplement).
The absolute risk increase for TE in patients with DDAT versus without was 0.02, signifying a 2% increased incidence of TE in patients with DDAT across the 9 studies used in this analysis (Figure V in the Data Supplement). However, because the rate of initiation of anticoagulation based on incident DDAT was not reported, the true number needed to harm may be higher or lower than this estimated risk. The AT diagnostic threshold in these studies ranged from <30 seconds to >14 minutes. We further stratified TE risk by varying AT diagnostic thresholds by comparing the 3 studies with DDAT threshold <1 minute with the 6 studies using ≥5 minutes. The RR of TE in patients with new-onset DDAT <1 minute was 1.77 (95% CI, 1.15-2.74; P=0.01), which did not reach statistical significance, compared with a significant RR of 3.86 (95% CI, 2.04-7.30; P<0.001) in patients with new-onset DDAT ≥5 minutes ( Figure 3A) .
Not all 9 studies reporting TE-adjudicated AEGs when diagnosing DDAT. When the 4 studies that did adjudicate AEGs were isolated, there was a 3.60 RR (95% CI, 2.06-6.30; P<0.001) compared with a nonsignificant 2.05 RR (95% CI, 1.06-3.97; P=0.03) for TE in the 5 studies in which DDAT was not adjudicated ( Figure 3B ). The absolute risk increase for studies with adjudicated EGMs was higher (3% versus 2% in studies without adjudicated EGMs; Figures VI and VII in the Data Supplement). Interestingly, studies with adjudicated AEGs had lower overall requirements for DDAT ranging from <1 minute to 6 minutes versus <1 minute to >14 minutes for studies with nonadjudicated DDAT. Of note, although overall rates of anticoagulation were reported by some groups, only a single study provided data on use of anticoagulation agents before and initiation after study enrollment in response to DDAT. Thus, the role of anticoagulant strategy and DDAT threshold could not be meta-analyzed.
DISCUSSION
The goals of this meta-analysis were 2-fold: (1) quantify the prevalence of new-onset DDAT, (2) determine the minimal cutoff duration of DDAT which was associated with a significantly increased risk of TE. We found that the prevalence of new-onset DDAT is substantial, affecting almost one quarter of patients receiving dual-chamber pacemakers or implantable cardioverter defibrillators. We further found that the presence of adjudicated DDAT of even <1 minute to 6 minutes may be clinically significant because use of this diagnostic threshold was associated with a markedly increased risk of TE (RR, 3.60; 95% CI, 2.06-6.30; P<0.001). Importantly, however, there remains a relative paucity of data on the safety and efficacy of anticoagulation based on specific episode duration of DDAT, and further definitive studies are still needed. 
Prevalence of DDAT
The rising prevalence of DDAT is a relatively recent phenomenon in an era in which prolonged cardiac monitoring has led to greater awareness of subclinical AT. 42 In our analysis, we found that new-onset DDAT was reported in the literature with incidence rates ranging from 8% to 51%. Taken together, we found a 23.0% incidence rate of new-onset DDAT among the 22 330 patients without prior history of AF or AT, meaning that just under one quarter of the population with prolonged cardiac monitoring are found to have DDAT.
The threshold for diagnosis of DDAT varied among these studies, ranging from episodes lasting <30 seconds to >150 minutes. Studies were reasonably distributed: 13 used a ≤1 minute cutoff, 9 diagnosed DDAT at thresholds >1 to 5 minutes, and 6 used >5 minute cutoffs. The incidence of DDAT was higher in studies with a lower diagnostic threshold-that is, more patients were diagnosed with DDAT in studies with a threshold of ≤1 minute versus those with >5 minute cutoff. This is not particularly surprising, but, importantly, it speaks to the difficulty in adequately evaluating the true incidence of DDAT because the diagnosis is not uniform.
Adjudication of DDAT
Adjudication is central to the appropriate diagnosis of DDAT, particularly when using relatively short thresholds for diagnosis. The clinical diagnosis of DDAT without adjudication has critical inherent flaws. First, cardiac devices have a limited memory and are often set to preserve more significant arrhythmias (ie, ventricular arrhythmias) over what are considered relatively more benign ATs. Without adjudication, AF is unable to be differentiated from far field artifact (ie, atrial oversensing of sensed or paced ventricular signals), noise, and other supraventricular tachycardia associated with lower TE risk, including atrial tachycardia with 1:1 atrioventricular conduction, atrioventricular nodal reentrant tachycardia, or atrioventricular reciprocating tachycardia. Furthermore, the incidence of AT induced by the pacing functions of the devices themselves is unknown. A subanalysis of the ASSERT trial (Asymptomatic Atrial Fibrillation and Stroke Evaluation in Pacemaker Patients and the Atrial Fibrillation Reduction Atrial Pacing Trial) evaluated the importance of adjudication through assessment of all recorded episodes of DDAT. The results were notable for a positive predictive value of 82.7% for episodes with a heart rate >190 beats per minute lasting >6 minutes. This correlated with a false-positive rate of 17.3%, which decreased to 1.8% when adjudicating episodes lasting >24 hours. 43 These data highlight the necessity of adjudication, particularly for relatively short durations of DDAT.
In this analysis, 14 of 28 studies comprising 49.1% of total patients discussed adjudication methods in their articles. The lack of adjudication in just over half of the included studies likely led to an overestimation of true DDAT incidence. With regards to the effect of adjudication on TE risk, 4 of 9 studies, comprising 4656 of 8903 (52.3%) patients, included data on TE incidence in DDAT patients. Importantly, the TE risk associated with DDAT in studies with adjudicated AEGs was significantly higher (RR, 3 
Risk of TE Associated With DDAT
An important goal of this study was to assess risk of DDAT with TE. The reported prevalence of TE associated with AF ranges from 1.5% to 23.5% in the literature. 44 The overall prevalence of TE in the studied cohort was 2.1%, which is comparable with the 2.7% reported prevalence of stroke in the general population. 44 This study found the prevalence of TE in patients with DDAT to be 3.7%, which was similar for patients with adjudicated and nonadjudicated DDAT (3.6% and 3.8%, respectively). Among patients with adjudicated AEGs, the RR of TE among patients with new-onset DDAT was RR 3.60 (P<0.001). This is comparable to the RR associated with TE in classically diagnosed AF (ie, from ECG or Holter monitoring) in the Framingham study, which ranges from 2.6 to 4.5, based on age. 3 The difficulty in establishing a clinically relevant minimum threshold for the diagnosis of DDAT is complicated by the temporal dissociation of DDAT and TE events, where prior studies have indicated that DDAT may infrequently occur contemporaneously with TE but rather often precede or follow TE events by weeks or even months. [13] [14] [15] [16] [17] Irrespective of causal mechanism, however, there is a clear signal that DDAT is significantly associated with increased risk. In this study, we found that overall there was a 2-fold increased risk of TE in 8181 patients with previously undiagnosed DDAT using diagnostic thresholds ranging from <30 seconds to >14 minutes. Using a threshold of <1 minute, the risk was lower (RR, 1.77; P=0.01) and not significantly associated with an increased risk of TE, versus a threshold of ≥5 minutes (RR, 3.86; P<0.001). This is indicative of a possible dose-dependent relationship between DDAT duration and risk of TE although may also be because of the presence of falsely positive diagnosis in nonadjudicated patients.
It should be noted, however, that while 6 of the 9 studies in this meta-analysis reporting DDAT and TE used diagnostic thresholds ≥5 minutes, the ASSERT trial accounted for just under half of the patients in this group (46%). A recent subanalysis of ASSERT by Van Gelder et al 45 noted that the most significant risk of TE was associated with DDAT lasting >24 hours, and patients with DDAT lasting ≥6 minutes to 24 hours had a similar risk of TE as patients without DDAT. In this analysis, we found that 3 additional trials-representing 31% of the patients-also independently noted a significantly increased risk of TE using the DDAT ≥5 minutes threshold although data on longer episodes in these studies remain limited. 17, 32, 35 Separately, although there are data that rigorously adjudicated short duration of DDAT are not associated with an increased risk of clinical events (ie, terminating within the visualized portion of the stored AEG, as in the RATE registry [Registry of Atrial Tachycardia and Atrial Fibrillation Episodes] 16 ), there remains uncertainty with respect to what minimum threshold of DDAT appropriately risk-stratifies patients. Importantly, this mirrors the pathobiology of TE in these patients. The mechanism of stroke is not limited to TE from stasis in the left atrial 9 appendage, and the presence sustained DDAT, even if short, may be a more general marker of risk.
Role of Anticoagulation in DDAT
Although the benefit of anticoagulation for patients with nonvalvular AF has been established, 18, 19 the optimal use of these agents in the new-onset DDAT population remains unknown. A few previous studies have examined this question through secondary end points but were not correctly designed, or powered, to adequately address this issue. 12, 46 There is only one study to our knowledge that primarily addressed this question: the IMPACT study, and it was stopped early because of futility with the validity of control group protocol called into question. 15 Unfortunately, of the 28 studies included in the meta-analysis, only IMPACT provided full details on the use of anticoagulation agents before and at the completion of the study. Two ongoing randomized control trials-ARTESiA (Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation) and NOAH (Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial High Rate Episodes)-seek to compare the risk of TE in patients with DDAT with treatment of placebo, antiplatelet agents (aspirin), or anticoagulation, with apixaban and edoxaban, respectively. 47, 48 These trials will hopefully provide more definitive data on the safety and efficacy of anticoagulation strategies for patients with DDAT. In the present state, we would suggest that physicians discuss the risks and benefits of anticoagulation on a case-by-case basis.
Limitations
Although there has been an increasing availability of data on DDAT, only studies with assessment of history of AT or AF in enrolled patients were included in this analysis, reducing the overall number of included trials, and which may limit generalizability of these findings. Moreover, only 10 of 28 studies separated baseline patient characteristics between patients with and without known history of AT/AF, so our analysis of the associated risk between these variables and the incidence of DDAT was limited to studies that reported these data. Furthermore, although we did elicit additional unpublished data for meta-analysis from authors who replied to our inquiry, we were not able to obtain patient-level data. Because of the lack of these specific data, we were unable to perform a meta-regression or develop a mixed model to identify covariates predicting DDAT. With that noted, we found that both overall incidence and associations of DDAT in this meta-analysis are in line with that reported by individual device studies, as well as what has been reported more generally for patients with AF in large population studies. Furthermore, we also found that lack of adjudication in prior device trials is associated with an overestimation of DDAT incidence and prevalence but that even relatively low thresholds for adjudicated DDAT are meaningfully associated with increased risk of TE. In addition, all of the included studies used cutoff times of episodes of AT for diagnosis, rather than total AT burden, when in fact this may be a better predictor of risk. Unfortunately, there is limited memory capacity on these devices, and these data are often not available. With the advent of cloud-based technology, it may soon be possible to save all events and assess overall DDAT burden and correlate it with TE risk. This may be a worthwhile end point in a future trial. Last, a significant limitation of our analysis is that only a single study included information on use of anticoagulation initiation based on DDAT incidence. This is a critical area for future inquiry and invites future investigation in this area.
Conclusions
New-onset DDAT is common, affecting close to one quarter of all patients with implanted pacemakers or defibrillators. Adjudication of atrial electrograms further identifies patients at risk for future TE, even when relatively short detection thresholds are used. These findings should increase the role of active engagement to review DDAT to confirm diagnoses.
